NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Crescent Biopharma, Inc. (CBIO) Stock Analysis

Crescent Biopharma, Inc. (CBIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CBIO

$20.88

+$0.48 (+2.35%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CBIO with… →

CBIO Key Statistics

As of Sep 4, 2026
Trading
Open
$20.09
Previous Close
$20.40
Day's Range
20.09–21.53
52-Week Range
8.72–27.41
Volume
239.70K
Valuation
Market Cap
$775.63M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
65.27
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.14
Financials (FY)
Revenue (FY)
$10.84M
Net Income (FY)
−$153.94M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
37.14M
1-Year Return
+52.52%
Dividend and dates
Avg Volume
329.93K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CBIO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+76.05%
2025−52.56%
2024−89.41%
2023−15.03%
2022 (partial year)+373.44%

As of September 4, 2026.

CBIO Valuation vs Biotechnology Median

Median of 656 stocks
MetricCBIOBiotechnology medianvs median
P/S ratio65.2715.264.3x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Crescent Biopharma, Inc. (CBIO) is capitalised at $775.63M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 69 employees.

The 52-week range on file runs from $8.72 to $27.41. The most recent close on file for CBIO is $20.88, dated September 4, 2026. That is +$0.48 (+2.35%) against the previous close. The latest close sits 139.45% above that 52-week low.

Financial Health

In fiscal 2025, Crescent Biopharma, Inc. reported revenue of $10.84M. The same year closed with a net loss of $153.94M. The reported profit margin is 0%. Trailing earnings per share are −0.14.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 65.27. On price-to-sales that is 4.3 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +52.52%. Across 3 years the annualized return works out at −48.96%. Annualized volatility over the trailing 4 years is 139.28%.

Growth & Income

No dividend is on file for CBIO.

Across the complete calendar years on file, 2023 returned −15.03% and 2024 returned −89.41%. Of the 3 complete calendar years on file, 0 finished higher. 2026 is still running; the price is +76.05% year to date.

Peer Comparison

Crescent Biopharma, Inc. (CBIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Crescent Biopharma, Inc. CBIO $775.63M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Crescent Biopharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Crescent Biopharma, Inc.

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Visit website →